This Week in The Pharmacy

/in /by

THE PHARMACY: There’s a great deal of interest in the Bio-tech sector at the moment, so we have opened our own Pharmacy to keep our readers up to speed.

 

OncoSil Medical commences Pivotal Clinical Trial

OncoSil Medical (ASX: OSL) has commenced its Pivotal Clinical Trial for its OncoSil™ localised radiation therapy for the treatment of pancreatic cancer. READ MORE…

Bionomics receives BNC105 Phase II trial results

Bionomics Limited (ASX: BNO) has announced the results of the DISRUPTOR-1 trial of BNC105 in patients with metastatic renal cancer. READ MORE…


Antisense Therapeutics commences stem Cell mobilisation trial

Antisense Therapeutics (ASX: ANP) has commenced dosing in its Phase I Stem Cell Mobilisation (SCM) Human Proof of Concept trial of ATL1102, the company’s second generation antisense drug targeting the VLA-4 receptor. READ MORE…

Viralytics announces International Institutional ownership

Viralytics Limited (ASX: VLA) has completed a $27.1 million equity offering that included a number of new institutional investors who specialize in healthcare. READ MORE…

Unilife Secures $60M debt financing

Unilife Corporation (ASX: UNS) has entered into a $60 million debt financing agreement with an affiliate of healthcare sector investment firm OrbiMed. READ MORE…


VivaGel®‐coated condom approved for marketing in Japan.

Starpharma (ASX: SPL) has been granted regulatory certification for marketing of the company’s VivaGel®‐coated condom in Japan. READ MORE…